Jan. 14 at 5:17 PM
$ARDX is a small-mid size biotech with TWO FDA approved drugs in the midst of an early growth sales ramp. How many companies can claim that? Very few.
Revenues this year expected to approach
$600M.
When that likely comes to fruition this year, the likelihood that the MC is near the current
$1.6B one is unlikely.
Q1 is always a bit of a wildcard due to seasonality but by year-end they’ll have the sales to show for it to justify a much higher market cap.
As much as I would have liked to have taken profits and moved on by now (Eff you CMS and Congress), I feel confident that simply holding tight this is primed to make me a hefty profit. Two great drugs address sizable markets with clear needs. Just a matter of time that the market recognizes and gives this company the valuation it deserves.
